Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Alexion Pharmaceuticals : Back on an important level

share with twitter share with LinkedIn share with facebook
share via e-mail
09/04/2019 | 09:53am EDT
long trade
Target price hit
Entry price : 97.68$ | Target : 107.65$ | Stop-loss : 93.49$ | Potential : 10.21%
The recent downturn has taken Alexion Pharmaceuticals shares close to a medium term support level around 95 USD. The timing for a long trade in the stock appears good.
Investors have an opportunity to buy the stock and target the $ 107.65.
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 94.63 USD in weekly data.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 45% by 2021.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.28 for the current year.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • With an enterprise value anticipated at 4.3 times the sales for the current fiscal year, the company turns out to be overvalued.
Alexion Pharmaceuticals : Back on an important level

Patrick Rejaunier
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2019 4 839 M
EBIT 2019 2 717 M
Net income 2019 1 907 M
Finance 2019 535 M
Yield 2019 -
P/E ratio 2019 12,7x
P/E ratio 2020 11,9x
EV / Sales2019 4,87x
EV / Sales2020 3,94x
Capitalization 24 082 M
Upcoming event on ALEXION PHARMACEUTICALS
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 155,48  $
Last Close Price 107,40  $
Spread / Highest target 71,3%
Spread / Average Target 44,8%
Spread / Lowest Target 12,7%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS11.20%24 082
CSL LIMITED25.08%72 022
BIOGEN INC.-21.36%43 646
GRIFOLS18.34%18 046
SAMSUNG BIOLOGICS CO LTD--.--%16 471
BIOMARIN PHARMACEUTICAL INC.-14.68%13 038